Phase 2 Ovarian Cancer Trial, Recruiting NCT07616037 Sponsor: Shanghai Zhongshan Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT07616037
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 40 years old
  • You are female
  • You are not planning to become pregnant from the time you sign the consent form until 2 months after your last dose of the study drug, and you are willing to use contraception methods approved by the study during this time
  • You meet at least two of the following signs of polycystic ovary syndrome (PCOS) based on 2023 international guidelines: (1) irregular periods — such as cycles shorter than 21 days or longer than 35–45 days depending on how long you have been menstruating, or fewer than 8 periods per year; (2) a certain appearance of the ovaries on ultrasound, showing 20 or more small follicles in at least one ovary; (3) higher-than-normal male hormone (androgen) levels, either shown in a blood test or through physical signs such as excess body hair

Who may not be able to join:

  • You have used hormonal contraceptives (such as the pill) within the past 2 months
  • You have a history of pancreatitis (inflammation of the pancreas) or pancreatic injury
  • You or a close family member has a history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a condition called multiple endocrine neoplasia type 2A or 2B
  • You have been diagnosed with type 1 or type 2 diabetes
  • You have another hormonal or gland-related condition that could also cause PCOS-like symptoms, such as certain adrenal gland disorders, a pituitary gland tumour, an underactive thyroid, or Cushing's syndrome
  • You are currently taking, or stopped less than 2 months ago, certain medications that affect reproductive hormones — such as GnRH drugs, anti-androgen treatments, or gonadotropins
  • You are currently taking, or stopped less than 1 month ago, certain medications that affect metabolism — such as metformin or similar diabetes-related drugs
  • You have had weight-loss (bariatric) surgery within the past 12 months
  • You have been treated with a type of medication called a GLP-1 receptor agonist within the past 12 months
  • You are currently pregnant or breastfeeding
  • You have a serious disease affecting a major organ such as the heart, liver, or kidneys, or you have any form of cancer
  • You have any other condition that the trial doctor feels could interfere with the study or make it unsafe for you to participate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-021-64041990

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change From Baseline in Free Androgen Index Over 24 Weeks of Treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov